Thursday, Amgen shares surged 5% as advisers told the Food and Drug Administration to warn patients not to use the company's top-selling anemia drug for head and neck cancer, breast cancer or in any case where patients might be cured of their cancer by chemotherapy.
Link to Article
Forbes.com
|
|
||||
|
This Month
Month Archive
RSS Newsfeeds
Main Page RSS
|
Friday, March 14
All The Wrong Numbers
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 14 Mar 2008 11:56 PM EDT
Future Technology Needs for Biomanufacturing: Special Session at IFPAC 2008 Identifies Goals and Gaps
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 14 Mar 2008 11:54 PM EDT
“We need to improve our ability to measure protein variants in real time and understand how to correlate to biological significance,” commented Duncan Low, PhD, scientific executive director at Amgen, in a January 28 presentation at the IFPAC 2008 meeting in Baltimore, Maryland. Low’s talk was part of a special...
Link to Article BioPharm International -- Advanstar Communications Inc.
Biogenerics Conference Addresses Scientific and Regulatory Issues Surrounding Biosimilars
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 14 Mar 2008 11:53 PM EDT
When considering how follow-on biologics will be compared to innovator products, Emily Shacter has a favorite question: If the drug substance of the innovator product is unavailable for testing, and therefore has to be tested in the formulation buffer or purified out of the formulated commercial product, how will we...
Link to Article BioPharm International -- Advanstar Communications Inc. |
Search
Links
|
||